Opioid misuse in gastroenterology and non-opioid management of abdominal pain

Eva Szigethy[1], Mitchell Knisely[2] and Douglas Drossman[3,4]

Abstract | Opioids were one of the earliest classes of medications used for pain across a variety of conditions, but morbidity and mortality have been increasingly associated with their chronic use. Despite these negative consequences, chronic opioid use is increasing worldwide, with the USA and Canada having the highest rates. Chronic opioid use for noncancer pain can have particularly negative effects in the gastrointestinal and central nervous systems, including opioid-induced constipation, narcotic bowel syndrome, worsening psychopathology and addiction. This Review summarizes the evidence of opioid misuse in gastroenterology, including the lack of evidence of a benefit from these drugs, as well as the risk of harm and negative consequences of opioid use relative to the brain–gut axis. Guidelines for opioid management and alternative pharmacological and nonpharmacological strategies for pain management in patients with gastrointestinal disorders are also discussed. As chronic pain is complex and involves emotional and social factors, a multimodal approach targeting both pain intensity and quality of life is best.

[1]*Departments of Psychiatry and Medicine, University of Pittsburgh, 3708 Fifth Avenue, Pittsburgh, Pennsylvania 15213, USA.*
[2]*School of Nursing, University of Pittsburgh, 3500 Victoria Street, Pittsburgh, Pennsylvania 15261, USA.*
[3]*Center for Functional GI & Motility Disorders, University of North Carolina, Bioinformatics Building, 130 Mason Farm Road, Chapel Hill, North Carolina 27599, USA.*
[4]*Drossman Gastroenterology PLLC, 901 Kings Mill Road, Chapel Hill, North Carolina 27517, USA.*

Correspondence to E.S.
szigethye@upmc.edu

Prescription opioid use has become a global epidemic. Between 2011 and 2013, opioid use more than doubled worldwide, with substantial increases occurring in North America, Europe and Oceania[1]. Despite the increasing trends worldwide, opioid consumption rates per capita in the USA and Canada far outpace those in other countries[2] (FIG. 1). One reason cited for this difference is that, in the rest of the world, opioids are not as frequently prescribed for chronic pain syndromes as they are in North America[3]. Similar trends are occurring in the UK[4,5], and its rates of opioid consumption in 2010 are comparable to rates at the inception (1999) of the opioid crisis in the USA[6]. Postulated reasons for lower opioid consumption in countries with national health systems, which are publicly funded, are that doctors have less incentive to over-prescribe and that prescription records are stored centrally, enabling patient misuse to be detected more quickly[7]. The notable rise in opioid prescribing over the past 15 years in the USA relates in part to the report by The Joint Commission in 2000, which indicated that pain was inadequately treated and better pain management was needed[8]. Notably, the commission provided little guidance on how best to achieve pain relief and did not recommend that the approach should involve increased use of opioids. In addition, opioids are recommended treatments on the WHO's three step 'analgesic ladder' for cancer pain[9]; however, this guideline has also been widely applied for managing chronic noncancer pain[10].

Although debate about the effectiveness of opioids in treating chronic noncancer pain exists, opioid misuse and overdose-related deaths continue to increase[11–13]. In 2014, >240 million opioid prescriptions were written[14], and nearly 19,000 deaths related to opioid prescriptions were reported in the US — a 3.4-fold increase in deaths since 2001 (REF. 15). In addition to mortality, chronic use of opioids is associated with serious medical morbidities, including addiction, and increased related medical resource utilization[16–19]. For example, in the USA, there was a nearly 300% increase in opioid-related emergency department visits between 2004 and 2011 (REF. 20), and >520,000 hospitalizations related to opioid abuse and dependence were reported in 2012[17]. Australia also had a 2.4-fold increase in opioid-related hospitalizations between 1998 and 2009 (REF. 21).

In 2010, 15.5 million people had opioid dependence globally, with the highest rates in North America (292.1 per 100,000), Eastern Europe (288.4 per 100,000) and Australia (278.6 per 100,000)[22]. In China, although heroin addiction remains the largest opioid problem, polydrug use, including prescription opioids, is on the

Key points

- Prescription opioid use is a global epidemic, with substantial increases in opioid-related morbidity and mortality around the world

- There is a lack of evidence supporting the use of opioids for the management of chronic abdominal pain

- Opioid use can have deleterious consequences on the gastrointestinal tract, including opioid-induced constipation and narcotic bowel syndrome

- Many promising non-opioid pharmacological and nonpharmacological alternatives for treating abdominal pain exist; however, additional research is needed to identify best practices for treating abdominal pain in individuals with gastrointestinal disorders

- If opioids are prescribed, it is essential to have strategies to monitor and manage opioid misuse, continually monitor risk–benefit clinical profiles, and prevent and treat addiction

rise[23]. In the US, the prevalence of opioid dependence in patients receiving prescription opioids is as high as 26% in primary care[24,25], the estimated rate of opioid misuse is 21–29%, and the rate of addiction is 8–12%[18]. The estimated rates of substance use disorder in patients with chronic pain seen in pain clinics are as high as 45% in the US[26,27]. In addition, nearly 53% of patients receiving treatment for chronic pain in two pain centres in Israel were found to have problematic opioid use[28].

Chronic opioid use can be particularly detrimental to the gastrointestinal tract and central nervous system, particularly in patients with pre-existing gastrointestinal conditions[19,29]. As opioids are prescribed predominantly in primary care and pain clinics[30,31], gastroenterologists often receive referral patients who are already on chronic opioid therapies. In fact, although gastroenterologists prescribe only 0.3% of opioids, the prevalence of pain is higher in individuals with gastrointestinal disorders than in the general public[32–34]. Estimates of chronic opioid use have ranged from 13% to nearly 50% in adults with IBD[33,35,36] and as high as 70% in hospitalized adult patients with IBD[37]. Rates of opioid use have been reported at >50% in patients with chronic pancreatitis[38] and at almost 20% in patients with IBS[39]. Among patients with chronic nonalcoholic pancreatitis, 39% had high scores on opioid misuse measures, with depressive symptoms, pain ratings, alcohol use and psychological quality of life being notable predictors[40]. Furthermore, prescription opioid use has been associated with increased hospitalization in patients with chronic pancreatitis[41] and with increased risk for infection in patients with Crohn's disease[36].

As opioid use and misuse are continuing to gain recognition as a global problem, increased awareness of opioid-induced gastrointestinal problems is necessary[42,43]. This Review summarizes the evidence of opioid misuse in gastroenterology, including the lack of evidence for a benefit from opioids and the risk of harm and negative consequences of opioid use relative to the brain–gut axis. Strategies to prevent opioid misuse, the treatment of pain for patients already on opioids and alternative intervention strategies for pain management in patients with gastrointestinal disorders are also discussed.

Opioids for gastrointestinal disorders

The evidence supporting the effectiveness of opioids for short-term use (<3 months) for chronic noncancer pain is largely focused on musculoskeletal pain[44]. Evidence for the efficacy of opioids for gastrointestinal pain is lacking. In chronic pancreatitis, one small randomized study assessed short-term (5 days) use of tramadol versus morphine and found that 67% of the tramadol group, compared with 20% of the morphine group, reported analgesia as "excellent" (REF. 45). There is a lack of randomized controlled trials showing the efficacy of opioids for chronic abdominal pain; additionally, gastrointestinal disease has been identified as a major cause of oral opioid ineffectiveness due to malabsorption[46]. Furthermore, existing evidence underscores concerns related to problematic opioid use in individuals with gastrointestinal disorders. In a study of chronic opioid users with Crohn's disease, 37% of patients with a concurrent functional gastrointestinal disorder (FGID) diagnosis were identified to be misusing opioids, compared with 9.6% of those without an FGID diagnosis[47]. The increased rate of opioid misuse in these patients might be explained by the presence of prior psychiatric diagnoses[37] and/or as part of a dissociative coping style for those patients with prior trauma history — a factor that has been independently linked to increased rates of IBS[48]. Additionally, a large epidemiological study indicates that ~5% of patients with IBD will become heavy users of opioids within 10 years after diagnosis[49]. This finding is of particular concern as the risk for addiction in patients with noncancer pain increases with higher dosing (>120 mg morphine equivalent) and chronic opioid therapy[50].

Opioid-induced gastrointestinal effects

Substantial evidence links opioid use to compounding and deleterious gastrointestinal-related adverse effects, collectively known as opioid-induced bowel dysfunction (OIBD). Among the most common opioid-induced gastrointestinal effects are constipation, nausea, abdominal pain or discomfort, gas, ileus, gall bladder contraction and gastro-oesophageal reflux[51,52]. In addition, in a large observational study among 6,273 patients with Crohn's disease, opioid use was significantly ($P < 0.001$) associated with serious infections and was also a significant predictor of death[36]. In a study of 2,055 patients taking opioids for noncancer pain, 57% reported constipation, 13% reported nausea, 11% reported abdominal pain and 10% reported increased gas as the most bothersome opioid-associated symptoms[51]. Opioid-induced constipation (OIC) is the most frequently reported gastrointestinal adverse effect, with estimates ranging from 15–90% of individuals taking opioids[53,54]. For instance, opioid users seeking care for abdominal pain in the emergency department were three times more likely than non-users to have constipation[55]. In addition, among 489 patients with chronic noncancer pain, OIC had a negative effect on quality of life, particularly on work performance and productivity (38%), performing activities of daily living (49%), social interactions (45%), sex lives (45%) and the ability to leave the house (43%)[56].

Other gastrointestinal symptoms reported with chronic opioid use are GERD (33%)[19] and opioid-induced oesophageal dysfunction[57]. In pooled data from two randomized controlled trials evaluating teduglutide (a glucagon-like peptide-2 analogue) in short-bowel syndrome ($n = 136$), patients taking opioids ($n = 52$) had significantly ($P = 0.0009$) greater adverse gastrointestinal effects than those who were not (51% versus 21% for abdominal pain, 42% versus 11% for nausea, 17% versus 8% for abdominal distension and 19% versus 6% for vomiting)[58].

The mechanisms underlying OIBD are complex but are primarily attributed to the high density of opioid receptors (μ-type, κ-type, δ-type) within the gastrointestinal tract, which, when activated, result in decreased motility and secretion[59,60] (FIG. 2). The effects of opioids on gastrointestinal motility (for example, delayed gastric emptying and slowing of intestinal transit) are associated predominantly with the activation of μ-opioid receptors in neurons of the enteric nervous system via cellular second-messenger systems such as cyclic AMP, chloride and potassium channels and protein kinases[29,61]. Opioid receptor antagonists can modulate both excitatory and inhibitory neural inputs in the gastrointestinal tract[62]. This interaction involves neurotransmitters such as acetylcholine, vasoactive intestinal peptide (VIP), nitric oxide (NO) and 5-hydroxytryptamine (serotonin)[60]. Inhibition of excitatory pathways, such as those involving acetylcholine or substance P, leads to the blockade of distention-induced peristaltic contractions, whereas suppression of inhibitory pathways such as NO signalling results in disinhibition of smooth muscle activity, elevation of muscle tone and nonpropulsive motility

(for example, spasms)[60,63]. Activation of δ-opioid receptors might also be involved in decreased gastrointestinal motility by altering pyloric tone[29].

Gastrointestinal secretion is predominantly mediated by the three types of opioid receptors located in the gut wall[60]. Opioids activate the sympathetic nervous system and inhibit acetylcholine and VIP activity, resulting in reduced secretion[60]. Opioids also reduce epithelial secretion and promote the absorption of electrolytes and water, worsening constipation and abdominal distress or pain[64]. Morphine administration has been associated with increased sphincter contraction and reduction in the emptying of pancreatic juice and bile, causing delayed digestion[65,66]. However, the effects of opioids on μ-opioid receptors in the lower oesophageal sphincter significantly ($P < 0.05$) decrease motility and pressure, resulting in oesophageal reflux[67,68]. Collectively, these opioid-induced gastrointestinal effects lead to nausea, vomiting, delayed gastric emptying and constipation. In addition, sphincter of Oddi dysfunction via μ-opioid receptor stimulation might also result in pancreatitis, as reported in studies testing the mixed opioid drug eluxadoline in patients with IBS[69,70].

Opioid use can also have deleterious effects for patients with liver diseases such as cirrhosis. Opioids are predominantly metabolized in the liver via oxidation, reduction or hydrolysis by the cytochrome P450 system (for example, CYP2D6, CYP2B6, CYP3A4); glucuronidation; or biliary excretion and elimination[71]. In a process known as the first-pass effect, orally ingested opioids, such as codeine, oxycodone and tramadol, are absorbed by the gastrointestinal tract and pass through the portal vein to undergo metabolism in the liver before the active metabolites of these medications reach the systemic circulation[72]. Hepatic dysfunction can result in reduced clearance of the drug from the blood or plasma and increased bioavailability and accumulation of the opioid[73]. A study in patients with cirrhosis who received an oral dose of morphine found that these patients had a mean elimination half-life of 5.5 h, compared with a mean of 3.3 h in a healthy control group ($P < 0.05$)[74]. The use of opioids in patients with liver disease can lead to, or aggravate, hepatic encephalopathy owing to the accumulation of opioid metabolites in the central nervous system[72,75].

Opioid tolerance, defined as the state of adaptation in which exposure to a drug induces changes that result in diminution of one or more of the drug's effects over time[44], can develop at different rates for different opioid-related effects. For instance, it develops quickly for effects such as nausea, sedation and cognitive impairment, whereas other effects such as constipation can occur much more slowly[76,77]. There are also differences in tolerance between central and peripheral targets. For example, a lack of tolerance in the colon leads to opioid-induced chronic constipation, in contrast to more proximal regions of the gut and also the brain, in which adverse effects such as nausea, vomiting and sedation improve over time[60]. The rate of development of analgesic tolerance to opioids has not been as definitively determined, although some studies suggest that it might not be a pervasive problem in long-term opioid use for chronic pain[78].


Figure 1 | **Trends in total opioid consumption by country between 1994 and 2014.** Graph indicates trends in total opioid consumption (mg per capita) per year among some of the world's most industrialized countries. Figure adapted with permission from REF. 205, Pain & Policy Studies Group, University of Wisconsin–Madison.

www.nature.com/nrgastro

www.manaraa.com

↑ Pressure of lower oesophageal sphincter

↓ Emptying of pancreatic juice and bile

↓ Pyloric tone

↓ Gastric emptying and motility

↓ Intestinal peristaltic contractions

↑ Absorption of fluids and electrolytes

↑ Anal sphincter tone

Figure 2 | **Summary of opioid-induced effects within the gastrointestinal system.** Opioid-induced adverse effects in the gastrointestinal system are primarily attributed to the activation of opioid receptors (μ-type, κ-type, δ-type) within the enteric nervous system, particularly in smooth muscle cells and in the terminals of sympathetic and sensory peripheral neurons in the gastrointestinal tract[60]. Consequences (symptoms) associated with opioid use include nausea, vomiting, constipation, abdominal distention, spasms and/or gastro-oesophageal reflux.

Opioid-induced constipation. OIC is characterized as a change in baseline bowel habits, such as reduced bowel movement frequency, development or worsening of straining during bowel movements, a sense of incomplete rectal evacuation and/or a harder stool consistency[79]. Involvement of other areas of the gastrointestinal tract causing small bowel ileus or gastroparesis is part of the wider spectrum of OIBD, although the mechanism is the same as that of OIC[29]. The motility effects of opioids are mainly caused by μ-opioid receptors, which are found throughout the gastrointestinal tract, whereas μ-opioid receptors in the brain and spinal cord are involved in analgesia[29]. In OIC, the activation of μ-opioid receptors leads to reductions in gastric emptying, propulsive contractions of the intestines and secretions from the intestines, pancreas and gallbladder[79]. OIC is also partially mediated by changes in water absorption owing to the effects of opioids on chloride channels[80]. These processes, together with increased pyloric and anal sphincter tone, lead to the symptoms of constipation.

Narcotic bowel syndrome. A growing number of studies report persistent abdominal pain in patients with chronic opioid use[19,51]. A specific type of persistent, yet under-recognized, abdominal pain termed narcotic bowel syndrome (NBS) has been identified in 6.4% of patients in the US with chronic opioid use[19]. NBS is defined as chronic or frequently recurring abdominal pain treated with high-dose opioids[81], and diagnostic criteria for clinical research are now available[82]. The nature or intensity of pain is not entirely due to diagnosis of a gastrointestinal disease, such as IBD or chronic pancreatitis, and even with pain resulting from another underlying diagnosis, there is an opioid-induced amplification of the pain[83]. To meet the diagnostic criteria for NBS, a patient must have had at least two of the following symptoms for the past 3 months with symptom onset at least 6 months before diagnosis: pain worsens or incompletely resolves with escalating doses of narcotics; there is a marked worsening of pain when the narcotic dose wanes and improvement when narcotics are re-initiated; and there is a progression of the frequency, duration and intensity of the pain episodes[84]. In addition to visceral pain that worsens with long-term or increasing doses of opioids, the hallmark symptom of NBS, other symptoms can include nausea, periodic vomiting, abdominal distension and constipation[83,84]. The inclusion of NBS in the Rome IV diagnostic criteria of FGIDs as a centrally mediated abdominal pain disorder[85] will increase its visibility among clinicians who manage these conditions.

The diagnosis of NBS can also be complicated by other physiological processes. For example, NBS, as a painful disorder, needs to be differentiated from OIC, which is characterized by bowel dysfunction, although pain might also be present. NBS is mediated by effects of opioids on the central nervous system resulting in central hyperalgesia, whereas OIC is caused by the peripheral effects of opioids on μ-opioid receptors affecting motility of the gastrointestinal tract[83]. Abdominal pain can also worsen during physiological withdrawal from opioids, but in this case, the pain occurs together with other symptoms of withdrawal such as lacrimation, yawning, rhinorrhoea, sweating, restlessness and diarrhoea[86]. Tolerance to opioids leading to escalating dosing is a concern but is not itself linked to worsening pain[86].

The paradoxical increase in pain associated with opioid use that characterizes NBS has been explained through several putative mechanisms (FIG. 3), including inflammatory glial cell activation in the dorsal horn[81,87], activation of excitatory pathways within a bimodal opioid regulation system[81,88] and the descending facilitation of pain at the level of the rostral medulla along with pain facilitation via dynorphin or cholecystokinin activation[81,89]. These mechanisms have been described in detail elsewhere[81–84,90]. Evidence suggests that chronic opioid use has compounding effects on glial cell activation and induction of visceral hyperalgesic effects[81]. Opioids bind directly to the μ-opioid receptors, which activate glia through the release of pro-inflammatory cytokines that bind to glial cell receptors, subsequently potentiating hyperalgesia[91]. In addition, opioids have been shown to have an indirect effect on glial cell activation in rats through the release of dynorphin within the spinal cord[92]. Furthermore, findings from a rat model of NBS supported morphine-induced spinal microglial activation caused by peripheral neuroimmune activation, and spinal dynorphin release

www.manaraa.com

mediated visceral hyperalgesia[93]. The activation of glial cells through Toll-like receptors (specifically, TLR4) has also been shown to mediate neuropathic pain and other deleterious opioid effects such as hyperalgesia, tolerance and physical dependence[94–96].

The bimodal opioid regulation system encompasses the excitatory and inhibitory effects on sensory neurons caused by opioids. This system is mediated by the stimulatory G protein-coupled receptors within the dorsal root ganglia[97]. Although opioids are generally considered to have inhibitory effects on afferent neurons and their signalling, evidence also suggests that chronic opioid use can induce excitatory effects (mediated by glutamate) on stimulatory G protein-coupled receptors, causing tolerance and hyperalgesia[81,88,97].

Prevention and treatment considerations

Patients with chronic pain who request opioids pose an ethical dilemma to clinicians who strive to find a balance between adequate pain relief and the risks of misuse and abuse of opioids. The basic ethical obligation of providers is to acquire current knowledge, skills and tools to assist in making prescribing decisions and uphold the ethical principles of beneficence, nonmaleficence, autonomy and justice[98]. In the absence of strong research evidence supporting the chronic use of opioids for abdominal pain, it is critical that prescribers use objective factors to conduct risk–benefit analyses[99,100] and not succumb to pressures to prescribe opioids only to increase patient satisfaction metrics[101,102]. One study in 2016 revealed that emergency room physicians perceived pressure to prescribe opioids to avoid administrative criticism and poor patient satisfaction[103]. Primary prevention is the most effective way to control the opioid epidemic[104]. However, should opioid use be warranted, for example, in patients in which the therapeutic benefit outweighs the many risks, appropriate steps need to be taken to mitigate the risks associated with opioids and ensure that they are not used as a first-line approach for treatment of any chronic noncancer pain. An algorithm for cautious opioid prescribing has been previously published[100], with key points highlighted in BOX 1. For patients who are already on opioids, recommended measures include repetitive monitoring of the risk–benefit ratio, optimizing non-opioid pain management strategies and tapering patients to the lowest possible opioid dose.

Opioid detoxification. As a first step in evaluating a pain treatment plan that includes opioids, an objective analysis of the risk–benefit ratio of chronic opioid prescription should be performed, and whenever possible, an opioid detoxification process to taper narcotic use should be considered. Published protocols outlining algorithms that use non-opioid strategies can help with chronic abdominal pain. Drossman *et al.*[105] demonstrated good short-term success with detoxification in patients with NBS, suggesting an opioid taper schedule of 10–33% reduction per day of morphine equivalent and attention to treating associated anxiety and withdrawal. During the opioid taper, short-term benzodiazepines for anxiety and agents such as clonidine for withdrawal symptoms were used[105]. This strategy should be used specifically for the purpose of detoxification, especially given an FDA warning in 2016 against prescribing opioids and benzodiazepines together on a chronic basis owing to synergistic brain-related adverse effects and an increased risk


Figure 3 | **Putative mechanisms for narcotic bowel syndrome and other models of opioid-induced hyperalgesia.** The bimodal opioid receptor switches from an inhibitory to an excitatory G protein state with chronic opioid exposure (1). Activation of descending pain pathways is mediated by several mechanisms including cholecystokinin (CCK) and release of dynorphin (Dyn), activation of calcium (Ca^{2+}) and potassium (K^+) channel-mediated membrane hyperexcitability, and protein kinase C (PKC)-induced increase in presynaptic *N*-methyl-D-aspartate (NMDA) receptor activation. On the presynaptic side, opioids paradoxically activate 'on cells' projecting from the rostral ventromedial medulla leading to increased dynorphin release. Opioids also activate NMDA receptors, which in turn can cause an influx in calcium and potassium through activated channels leading to increased PKC. These mechanisms sensitize the postsynaptic neuron to pain (2). Opioids induce the immune-system-related glial cells to release pro-inflammatory cytokines into dorsal horn of the spinal cord (3). DRG, dorsal root ganglion.

Box 1 | Risk mitigation when prescribing opioids

- Screen for opioid misuse by using available validated measures and avoid using opioids or taper the dose for patients with untreated substance abuse and/or dependence.

- Monitor appropriate use of opioids by using state or country prescription drug monitoring programmes and random toxicology screens.

- Form a treatment contract with patients that includes informed consent about risks versus benefits, such as the risk of overdose, addiction or serious adverse effects and increased risk of death.

- Discuss alternative treatment options with patients.

- Work within a multidisciplinary team (for example, physicians, nurses, mental health counsellors or addiction specialists and social workers) with resources for treating addiction and comorbid mental conditions.

- Provide access to naloxone as a rescue medication.

- Provide the lowest possible dose of opioids, avoid 'as-needed' dosing and evaluate the risk–benefit ratio at least every 3 months. Doses >80 mg per day of morphine equivalent are best avoided owing to increased risks of adverse events.

- Taper long-acting opioids when risks are greater than benefits, and supplement the taper with non-opioid analgesics and behavioural interventions.

- Avoid concomitant use of benzodiazepines owing to increased risks of overdose and synergistic adverse effects.

- Provide careful documentation in the medical record.

of mortality[106]. The protocol[105] also follows the wisdom for the use of off-label non-opioid pain medication substitutions such as tricyclic antidepressants (TCAs) or serotonin–noradrenaline reuptake inhibitors (SNRIs) to manage chronic abdominal pain[107,108]. Gabapentin, a GABA analogue anticonvulsant, has shown promise in reducing opioid-induced hyperalgesia in patients with chronic pain by reducing central sensitization[109]. Preoperative gabapentin administration has been shown to significantly ($P < 0.001$) reduce postoperative opioid consumption in a meta-analysis of 1,793 patients who underwent abdominal, genitourinary, orthopaedic or thoracic surgery[110]. In a study of experimentally induced opioid withdrawal, co-administration of palonosetron (a 5-hydroxytryptamine receptor 3 (5-HT$_3$) antagonist) with hydroxyzine reduced the severity of withdrawal[111]. In addition, a Cochrane review published in 2017 identified buprenorphine as more effective than alternatives (for example, clonidine or lofexidine) in terms of severity of withdrawal, duration of treatment and likelihood of completing treatments[112].

Although developed for patients with NBS, this detoxification approach can be useful for moving from opioid to non-opioid pain management strategies for other patients with chronic abdominal pain, such as those with IBS, IBD or chronic pancreatitis. TCAs can improve the global symptoms of IBS[113], and the noradrenergic modulatory action of TCAs might have anti-inflammatory effects[114] and might also inhibit TLR4 and TLR2 activation[94]. These TCA-linked pathways might also be beneficial for patients with IBD[115]. In a double-blind placebo-controlled trial of patients with IBD, the SNRI duloxetine was more efficacious than placebo in reducing depression, anxiety and the severity of gastrointestinal symptoms and chronic pain[116]. In addition, a study evaluating the effects of antidepressant therapies on global symptoms in patients with functional dyspepsia found

that a TCA (amitriptyline) significantly reduced dyspepsia symptoms, whereas the selective serotonin reuptake inhibitor (SSRI) escitalopram did not[117]. Although SSRIs have not been shown to directly reduce abdominal pain, they can have an indirect effect by reducing associated anxiety and depression[118,119]. Serotonergic psychoactive agents can affect other aspects of gastrointestinal functioning, such as accelerating small bowel transit, enhancing gastric accommodation, increasing colonic compliance and reducing sensations of distension[120].

Alternative pharmacological treatments. Off-label medications such as mirtazapine, a tetracyclic antidepressant, can be prescribed as an alternative, or in addition, to TCAs or SNRIs, particularly if there is persistent sleep disturbance or nausea. Low-dose quetiapine, an antipsychotic, has also been recommended as an adjunct medication for pain in patients with refractory FGIDs but requires monitoring for possible adverse effects, such as metabolic syndrome, sedation and involuntary movements[121]. Anticonvulsant medications such as gabapentin and pregabalin have shown efficacy in reducing pain in patients with pancreatitis, IBS or IBD, mediated via effects in the brain[122–126]. Several review articles published elsewhere cover the risks and benefits of using other psychotropic agents for the management of abdominal pain[81,87,114,127,128]. TABLE 1 summarizes the empirical evidence for the use of psychotropic agents for chronic abdominal pain[113,116,129–133]; however, the findings of these meta-analyses should be interpreted in light of several general limitations, including overlap of included studies, small sample sizes, diversity of medications within each drug class, lack of uniformity of study endpoints and substantial heterogeneity among the studies analysed. In clinical studies, antispasmodics, peppermint oil, 5-HT$_3$ receptor antagonists and mixed opioid agents have also demonstrated efficacy for the treatment of pain and other symptoms in IBS[69,134].

In terms of determining the best strategy for treating abdominal pain in each unique patient, previous exposure to psychotropic medications, drug allergies or sensitivities and the presence of comorbid medical and psychiatric conditions need to be considered. In addition, psychological drivers of pain (for example, the unconscious meaning of pain, secondary gain, poor cognitive flexibility, catastrophizing and fear-based attentional bias) can be important measurable confounders of other pain reduction strategies if not addressed as part of a comprehensive treatment plan (see BOX 2 for definitions of these psychological terms)[135,136].

The management of OIC is also best achieved by stopping opioid use. Osmotic-type laxatives such as polyethylene glycol are most commonly used[79]. Alternatives to laxatives include more prolonged-release formulations that contain naloxone (an opioid antagonist), such as oxynal, which have also shown some benefit for improving bowel function[137]. Peripherally acting μ-opioid receptor antagonists (PAMORAs), including agents such as methylnaltrexone, alvimopan and naloxegol (NKTR-118), are efficacious for treating patients with more persistent OIC[138,139]. These agents selectively bind

to μ-opioid receptors in the gastrointestinal tract to block the peripheral effects of opioids while sparing the central opioid receptors that contribute to the analgesic effects[140]. Newer laxatives such as lubiprostone and prucalopride have shown efficacy in treating OIC. Lubiprostone activates chloride channel protein 2 in gastrointestinal epithelial cells, resulting in the secretion of chloride and ultimately softened stool consistency[141]. Prucalopride alters motility by activating selective 5-HT$_4$ receptors in the gut and has been shown to be effective in treating both chronic and opioid-induced constipation[142,143]. Other agents under development to treat OIC include the PAMORA naldemedine and the guanylate cyclase receptor agonist linaclotide[144]. Recommendations on

Table 1 | Evidence for antidepressant medication efficacy for treating abdominal pain

Study (design)	Number of studies (number of participants)	Medication versus comparison groups	Duration of therapy (weeks)	Selected outcome assessment	Summary of evidence of efficacy
TCAs					
Ford et al.[129] (meta-analysis)	11 RCTs (744 patients with IBS)	TCAs (amitriptyline, desipramine, doxepin, imipramine, nortriptyline, trimipramine) versus placebo	4–12	Global IBS symptoms or abdominal pain	• 43% ($n = 180$) of patients receiving TCAs had no improvement of symptoms, compared with 63.7% ($n = 209$) receiving placebo • TCAs showed no difference in improvement of symptoms when compared with placebo (RR 0.67, 95% CI 0.58–0.77)
Ruepert et al.[130] (meta-analysis)	4 RCTs (320 patients with IBS)	TCAs (amitriptyline, desipramine, doxepin) versus placebo	4–12	Abdominal pain (dichotomous outcome)	Subgroup analyses of abdominal pain showed significant benefit from TCAs (RR 1.26, 95% CI 1.03–1.55)
Xie et al.[113] (meta-analysis)	5 RCTs (428 patients with IBS)	TCAs (amitriptyline, desipramine, imipramine, trimipramine) versus placebo	4–12	Global symptom relief, abdominal pain	Treatment with TCAs was associated with an improvement in global symptoms (RR 1.36, 95% CI 1.07–1.71)
SSRIs					
Ford et al.[129] (meta-analysis)	7 RCTs (356 patients with IBS)	SSRIs (citalopram, fluoxetine, imipramine, paroxetine) versus placebo	6–12	Global IBS symptoms or abdominal pain	• 45.5% ($n = 80$) of patients receiving SSRIs had no improvement in symptoms, compared with 67.2% ($n = 121$) receiving placebo • No improvement of IBS symptoms with SSRIs compared with placebo (RR 0.68, 95% CI 0.51–0.91), but with statistically significant heterogeneity between studies ($I^2 = 49\%$, $P = 0.07$)
Ruepert et al.[130] (meta-analysis)	4 RCTs (197 patients with IBS)	SSRIs (citalopram, fluoxetine, paroxetine) versus placebo	6–12	Abdominal pain	Subgroup analyses for abdominal pain showed no benefit from SSRIs (RR 2.29, 95% CI 0.79–6.68)
Xie et al.[113] (meta-analysis)	6 RCTs (371 patients with IBS)	Citalopram, fluoxetine, paroxetine versus placebo	6–12	Global symptom relief, abdominal pain	SSRIs produced no difference in improvement of symptoms compared with placebo (RR = 1.38, 95% CI 0.83–2.28) and produced no improvement in abdominal pain or quality of life
SNRIs					
Brennan et al.[131] (open-label pilot study)	NA (14 patients with IBS)	Duloxetine*	12	CGI, IBS symptoms, anxiety, quality of life, disability	Duloxetine was associated with significantly improved quality of life and significantly reduced pain, severity of illness, loose stool, disability and anxiety (all $P < 0.05$)
Daghaghzadeh et al.[116] (blind RCT)	NA (35 patients with IBD)	Duloxetine versus placebo	12	Anxiety, depression, colitis activity, quality of life	• Symptom severity was significantly reduced in duloxetine group compared with placebo ($P = 0.02$) • Depression and anxiety were significantly reduced in duloxetine group compared with placebo ($P = 0.041$ and 0.049, respectively) • Physical, psychological and social dimensions of quality of life were significantly increased ($P = 0.001$, 0.038, and 0.015, respectively)
Kaplan et al.[132] (Open-label pilot study)	NA (13 patients with GAD and IBS)	Duloxetine*	12	CGI, IBS symptoms, anxiety	Significant improvements in symptom severity ($P < 0.001$), anxiety ($P < 0.01$), and CGI improvement ($P < 0.001$) and severity scales ($P < 0.001$)
Lewis-Fernández et al.[133] (open-label pilot study)	NA (17 patients with current MDD and IBS)	Duloxetine*	12	CGI, IBS symptoms, depression	• Abdominal pain severity decreased by 56% ($P < 0.0001$) • Significant improvement in gastrointestinal symptoms ($P < 0.001$) and depression ($P < 0.001$)

CGI, Clinical Global Impression scale; GAD, general anxiety disorder; MDD, major depressive disorder; NA, not applicable; RCT, randomized controlled trial; RR, relative risk; SNRI, serotonin–noradrenaline reuptake inhibitors; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant. *No comparison group.

Box 2 | **Definitions of psychological confounders of opioid management**

- **Cognitive flexibility:** The ability to adapt and apply a broad range of coping strategies to face new or unexpected challenges.
- **Catastrophizing:** A cognitive distortion or irrational thought that something is much worse than it actually is such that imagined worst-case scenarios are treated as inevitable.
- **Fear-based attentional bias:** The differential attention towards one stimulus class (for example, fear of pain) over another (neutral emotion) such that this selective processing of threatening information leads to hypervigilance and avoidance behaviour instead of adaptive coping or acceptance.
- **Unconscious meaning of pain:** A process by which an unbearable or unacceptable emotion (for example, rage) is converted to a more acceptable physical symptom; this process occurs outside of conscious awareness as a solution to avoid inner conflict.
- **Secondary gain:** The advantage that occurs in different domains (for example, increased attention from others, disability benefits, or being excused from responsibilities) owing to a real or stated illness.

initiating prescription therapies for OIC have previously been published and include the use of validated assessment tools to determine when treatments for OIC should be initiated[145]. Tools to assess for OIC, such as the Bowel Function Index[146] and the Patient Assessment of Constipation Symptoms[147], include the evaluation of patient-reported bowel symptoms (for example, incomplete evacuation, straining, stool consistency and ease of defecation).

Nonpharmacological treatments for pain. In addition to non-opioid pharmacological management of pain, there is a growing body of literature supporting behavioural interventions as part of a comprehensive treatment plan for chronic abdominal pain, even when opioids are not involved[148]. In fact, there is a large body of literature supporting the use of various psychosocial interventions, including cognitive behavioural therapy (CBT)

or mindfulness training, for other types of chronic pain[149–151]. Several meta-analyses of randomized controlled trials targeting pain in IBS showed that antidepressants and behavioural interventions such as CBT outperformed placebo and standard medical treatments[129,152–155]. Cognitive behavioural interventions in addition to usual care also show promise in treating chronic pain in patients with IBD[156,157]. However, pain in IBD studies is often measured as an item on another scale (for example, quality of life), and optimal efficacy of CBT has been hampered by study design issues and high attrition rates[158]. Other behavioural interventions, such as hypnosis and mindfulness meditation, have demonstrated efficacy in reducing psychiatric morbidity and chronic abdominal pain and improving quality of life across different gastrointestinal conditions (see TABLE 2 for a summary of meta-analyses evaluating the efficacy of behavioural interventions for chronic abdominal pain and associated symptoms)[159–168].

Behavioural interventions in patients with IBS appear to have their strongest effects on visceral pain via modulation of mood (anxiety, depression)[169]. Negative emotional states and stress have been shown to alter gut physiology, motility and sensitivity to nociceptive stimuli[170]. Neuroplastic changes in emotional and cognitive brain centres are known to amplify pain signals from the viscera[148,171]. The fear–avoidance model of chronic pain has the most support in explaining how behavioural interventions can alter multiple aspects of central processing of pain, such as the sensory–discriminative and motivational–affective domains (discussed in detail elsewhere[148]). These therapy-conditioned responses in the brain can influence the gastrointestinal tract by multiple pathways such as the autonomic nervous system, the hypothalamic–pituitary–adrenal stress axis, the immune system and the microbiome[172].

Table 2 | **Sample of meta-analyses evaluating behavioural interventions for abdominal pain and/or global gastrointestinal symptoms**

Study (design)	Number of studies included (number of participants)	Behavioural interventions included	Outcomes of interest	Summary of evidence for behavioural interventions
Altayar et al.[154] (meta-analysis)	15 RCTs (1,352 adults with IBS)	CBT, psychoeducational courses, mind–body therapy, psychodynamic interpersonal therapy and contingency management	IBS symptom severity, abdominal pain and quality of life	• Psychotherapy significantly associated with improvements in IBS symptom severity scale scores (SMD –0.618; 95% CI: –0.853 to –0.383), abdominal pain (SMD, –0.282; 95% CI: –0.562 to –0.001) and IBS-Quality of Life Questionnaire (SMD, 0.604; 95% CI: 0.440–0.768) • No significant differences in diarrhoea or constipation scale scores
Aucoin et al.[161] (meta-analysis)	7 RCTs for FGIDs (592 participants with an FGID)	Mindfulness-based therapies	IBS symptom severity and quality of life	• Mindfulness-based therapy had significant effects on IBS severity (pooled $d = 0.59$; 95% CI: 0.33–0.86) and quality of life (pooled $d = 0.56$; 95% CI: 0.47–0.79) at end of intervention • Non-significant improvement in IBS symptoms was noted at follow-up (2–18 months after end of intervention)
Laird et al.[153] (meta-analysis)	41 RCTs (2,290 adults with IBS)	CBT, mindfulness, relaxation, hypnosis and emotional awareness training	GI symptom severity	• Psychotherapy had a medium effect (reducing) on gastrointestinal symptom severity ($d = 0.69$, $P < 0.001$) immediately after treatment, and the effect continued to be significant at short-term (1–6 months, $d = 0.76$, $P < .001$) and long-term (6–12 months, $d = 0.73$, $P < 0.001$) assessments
Lee et al.[159] (meta-analysis)	7 RCTs (374 adults with IBS)	Hypnotherapy	Abdominal pain, constipation and diarrhoea	• Significant change in abdominal pain scores in the hypnotherapy group at 3 months (SMD, –0.83; 95% CI: –1.65 to –0.01) • No significant differences and/or changes noted in constipation or diarrhoea scores

CBT, cognitive behavioural therapy; FGID, functional gastrointestinal disorder; GI, gastrointestinal; RCT, randomized controlled trial; SMD, standardized mean difference.

Many barriers to patients receiving nonpharmacological pain management therapies still exist, including geographical distance, shortage of behavioural intervention providers and long waiting lists[173]. The availability and demonstrated benefits of scripted hypnosis protocols can make this treatment feasible by trained medical staff[174]. The development of effective virtual behavioural therapy options (web-based approaches) to reduce pain has helped with the access problem, with patients now able to receive the adequate level of psychotherapy in the comfort of their homes, which is also associated with long-term efficacy[175–177].

A strong physician–patient relationship to facilitate management of pain and other medical conditions is critical, and this relationship should include good communication, empathic engagement and addressing problems and treatment as a dyadic team[178–181]. This approach is particularly important as patients with pain often expect a quick fix without understanding the long-term consequences of opioid therapies[180,182]. Working in a setting in which a broader team (nurses, social workers, behavioural specialists) is involved can help patients learn new coping strategies to reduce pain perception and help them understand the limitations associated with chronic opioid use. For managing people with gastrointestinal disorders, different models of integrated behavioural medical care and transdisciplinary treatment might be more effective than collaborative or integrated models, in which team members from different disciplines might be co-located but still practising in their particular niche[183].

Psychopathological considerations. Psychopathology, especially mood and anxiety disorders, is commonly associated with opioid use. In a study of 34,653 people, nonmedical opioid use was associated with mood disorders, major depressive disorder, bipolar disorder and anxiety disorders[184]. Psychiatric comorbidity is also associated with reduced opioid analgesia and increased opioid misuse[185]. Depressive symptoms have been reported to moderate the relationship between pain levels and opioid misuse[186]. Depression and anxiety were identified to mediate the relationship between catastrophizing and opioid misuse in another chronic pain population[187].

There can be serious centrally mediated consequences of opioids[188], as opioid receptors are also found in the brain. These receptors also bind endogenous opioids (endorphins) that are involved in pain perception and modulation of reward mechanisms and mood (euphoria)[188]. These positive effects of opioids can be reinforcing, leading to repeated administration, which, in vulnerable individuals, becomes addiction. These risk factors for addiction include a biological predisposition for opioid-induced craving, loss of control or compulsive use[189]. It is important to distinguish between physical dependence (withdrawal syndrome following abrupt dose reduction or administration of an antagonist) and addiction (loss of control over use, continued use despite adverse consequences, preoccupation with obtaining and using the drug)[18].

An area that warrants attention is that relapse rates for patients with chronic pain who have been tapered from opioids are high and require long-term treatment algorithms to be developed[105]. One under-recognized cause of such relapse is opioid addiction. In a small study evaluating detoxification in NBS, the patients who had high relapse rates were those who had high opioid misuse scores, indicating that those addicted to opioids need greater intervention[105]. For patients who show signs of opioid addiction (problematic behaviours consistent with craving, loss of control or compulsive use), it is necessary to refer them to appropriate substance abuse clinics where they can have access to agonists (methadone or partial agonists such as buprenorphine) and appropriate counselling. In 2015, transdiagnostic and integrative therapies such as Acceptance and Commitment Therapy were found to be more efficacious than traditional CBT or 12-step programmes for patients with substance abuse disorders[190]. Opioid addiction can also lead to intravenous drug abuse[191], increasing the risks of contracting HIV and hepatitis C[192,193].

For treatment-refractory patients with chronic pain and addiction, several nonpharmacological biological interventions are in development. These options include peripheral nerve stimulation, as well as brain stimulation procedures such as transcranial magnetic stimulation, transcranial direct current stimulation, high-definition transcranial direct current stimulation and deep brain stimulation[194–198]. All of these approaches are thought to influence the modulation of pain in the peripheral or central nervous system by inhibiting the transmission of pain signals[194,196]. For example, published case reports have indicated the subcutaneous placement of peripheral nerve stimulator electrodes in the location or dermatome associated with chronic abdominal pain improved pain severity and function and decreased the use of pain medications[194]. The risk–benefit ratio of these approaches for patients with abdominal pain has yet to be determined, and large controlled trials are needed[197,198].

A small group of patients do benefit from chronic opioid use for pain management without developing tolerance, hyperalgesia or addiction[78]. For this group of patients, it is essential that prescribing physicians follow the legal recommendations in their state-run or national prescription drug monitoring programmes (PDMP),

forming drug contracts with patients, including random toxicology screens, adhering to careful documentation in the electronic health records, using naloxone to treat opioid overdoses and continuing to explore non-opioid options with their patients. Several validated instruments for evaluating behaviours related to opioid misuse are available, including the Current Opioid Misuse Measure[199] and the Screener and Opioid Assessment for Patients with Pain[200], among others. Furthermore, almost all states in the USA have authorized PDMPs, and over half are permitted to share data with other state PDMPs[201]. In addition, Australia is seeking to establish a national PDMP[202]. PDMPs enable prescribers to assess aberrant behaviours (for example, 'doctor shopping') and have been associated with reductions in opioid prescribing[201]. The European Monitoring Centre for Drugs and Drug Addiction monitors trends in drug use for countries in the European Union and provides resources related to harm reduction interventions for drug use[203,204].

Conclusions

Opioid misuse is a global epidemic and has led to substantial increases in opioid-related abuse and mortality. Given the lack of evidence supporting the effectiveness of opioids for managing chronic pain, as well as the debilitating effects of those drugs on both the gastrointestinal and central nervous systems, alternative approaches to pain management in patients with gastrointestinal conditions must be employed. Alternatives to prescribing opioids in this population should include non-opioid pharmacological agents, behavioural interventions, strong physician–patient relationships and transdisciplinary team approaches. This Review underscores the need for additional research (BOX 3) on non-opioid pharmacological and nonpharmacological interventions, as well as different formulations and/or delivery mechanisms of opioids for treating chronic abdominal pain in patients diagnosed with gastrointestinal disorders to reduce pain intensity, improve quality of life and avoid addiction.

1. Berterame, S. et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet 387, 1644–1656 (2016).
2. University of Wisconsin–Madison Pain & Policy Studies Group. Opioid consumption data. Pain & Policy Studies Group http://www.painpolicy.wisc.edu/opioid-consumption-data (2017).
3. Denisco, R. A., Chandler, R. K. & Compton, W. M. Addressing the intersecting problems of opioid misuse and chronic pain treatment. Exp. Clin. Psychopharmacol. 16, 417–428 (2008).
4. Zin, C. S., Chen, L. C. & Knaggs, R. D. Changes in trends and pattern of strong opioid prescribing in primary care. Eur. J. Pain 18, 1343–1351 (2014).
5. Ruscitto, A., Smith, B. H. & Guthrie, B. Changes in opioid and other analgesic use 1995–2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur. J. Pain 19, 59–66 (2015).
6. Weisberg, D. F., Becker, W. C., Fiellin, D. A. & Stannard, C. Prescription opioid misuse in the United States and the United Kingdom: cautionary lessons. Int. J. Drug Policy 25, 1124–1130 (2014).
7. The Economist. The problem of pain. The Economist http://www.economist.com/news/international/21699363-americans-are-increasingly-addicted-opioids-meanwhile-people-poor-countries-die (2016).
8. Berry, P. H. & Dahl, J. L. The new JCAHO pain standards: implications for pain management nurses. Pain Manag. Nurs. 1, 3–12 (2000).
9. World Health Organization. WHO's cancer pain ladder for adults. World Health Organization http://www.who.int/cancer/palliative/painladder/en/ (2016).
10. Manubay, J., Muchow, C. & Sullivan, M. Prescription drug abuse: epidemiology, regulatory issues, chronic pain management with narcotic analgesics. Prim. Care 38, 71–90 (2011).
11. Chang, H. Y., Daubresse, M., Kruszewski, S. P. & Alexander, G. C. Prevalence and treatment of pain in EDs in the United States, 2000 to 2010. Am. J. Emerg. Med. 32, 421–431 (2014).
12. Daubresse, M. et al. Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000–2010. Med. Care 51, 870–878 (2013).
13. Rudd, R. A., Aleshire, N., Zibbell, J. E. & Gladden, R. M. Increases in drug and opioid overdose deaths — United States, 2000–2014. MMWR Morb. Mortal. Wkly Rep. 64, 1378–1382 (2016).
14. Department of Health and Human Services, USA. The opioid epidemic: by the numbers. HHS.gov http://www.hhs.gov/sites/default/files/Factsheet-opioids-061516.pdf (2016).
15. National Institute on Drug Abuse. Overdose death rates. National Institute on Drug Abuse https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates (2015).
16. Inocencio, T. J., Carroll, N. V., Read, E. J. & Holdford, D. A. The economic burden of opioid-related poisoning in the United States. Pain Med. 14, 1534–1547 (2013).
17. Ronan, M. V. & Herzig, S. J. Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2002–2012. Health Aff. 35, 832–837 (2016).
18. Vowles, K. E. et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 156, 569–576 (2015).
19. Tuteja, A. K., Biskupiak, J., Stoddard, G. J. & Lipman, A. G. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol. Motil. 22, 424–e96 (2010).
20. Substance Abuse and Mental Health Services Administration (SAMHSA). National estimates of drug-related emergency department visits, 2004–2011. Substance Abuse and Mental Health Services Administration (SAMHSA) http://www.samhsa.gov/data/emergency-department-data-dawn/reports (2014).
21. Blanch, B., Pearson, S. A. & Haber, P. S. An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br. J. Clin. Pharmacol. 78, 1159–1166 (2014).
22. Degenhardt, L. et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction 109, 1320–1333 (2014).
23. Marienfeld, C. Heroin addiction, methadone, and HIV in China. Lancet Psychiatry 3, 799–800 (2016).
24. Boscarino, J. A. et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction 105, 1776–1782 (2010).
25. Fleming, M. F., Balousek, S. L., Klessig, C. L., Mundt, M. P. & Brown, D. D. Substance use disorders in a primary care sample receiving daily opioid therapy. J. Pain 8, 573–582 (2007).
26. Katz, N. P. et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth. Analg. 97, 1097–1102 (2003).
27. Passik, S. D., Kirsh, K. L., Donaghy, K. B. & Portenoy, R. K. Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin. J. Pain 22, 173–181 (2006).
28. Feingold, D., Goor-Aryeh, I., Bril, S., Delayahu, Y. & Lev-Ran, S. Problematic use of prescription opioids and medicinal cannabis among patients suffering from chronic pain. Pain Med. 18, 294–306 (2016).
29. Hughes, P. A., Costello, S. P., Bryant, R. V. & Andrews, J. M. Opioidergic effects on enteric and sensory nerves in the lower GI tract; basic mechanisms and clinical implications. Am. J. Physiol. Gastrointest. Liver Physiol. 311, G501–G513 (2016).
30. Levy, B., Paulozzi, L., Mack, K. A. & Jones, C. M. Trends in opioid analgesic-prescribing rates by specialty, U. S., 2007–2012. Am. J. Prev. Med. 49, 409–413 (2015).
31. IMS Institute for Healthcare Informatics. Medicines used and spending in the U. S.: A review of 2015 and outlook to 2020 (IMS Institute for Healthcare Informatics, 2016).
32. Bharucha, A. E., Chakraborty, S. & Sletten, C. D. Common functional gastroenterological disorders associated with abdominal pain. Mayo Clin. Proc. 91, 1118–1132 (2016).
33. Buckley, J. P., Kappelman, M. D., Allen, J. K., Van Meter, S. A. & Cook, S. F. The burden of comedication among patients with inflammatory bowel disease. Inflamm. Bowel Dis. 19, 2725–2736 (2013).
34. Buckley, J. P., Cook, S. F., Allen, J. K. & Kappelman, M. D. Prevalence of chronic narcotic use among children with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 13, 310–315.e2 (2015).
35. Cross, R. K., Wilson, K. T. & Binion, D. G. Narcotic use in patients with Crohn's disease. Am. J. Gastroenterol. 100, 2225–2229 (2005).
36. Lichtenstein, G. R. et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am. J. Gastroenterol. 107, 1409–1422 (2012).
37. Long, M. D., Barnes, E. L., Herfarth, H. H. & Drossman, D. A. Narcotic use for inflammatory bowel disease and risk factors during hospitalization. Inflamm. Bowel Dis. 18, 869–876 (2012).
38. Nusrat, S., Yadav, D. & Bielefeldt, K. Pain and opioid use in chronic pancreatitis. Pancreas 41, 264–270 (2012).
39. Dorn, S. et al. Patients with IBS commonly use narcotics [abstract]. Gastroenterology 138 (Suppl. 1), W1378 (2010).
40. Barth, K. S. et al. Screening for current opioid misuse and associated risk factors among patients with chronic nonalcoholic pancreatitis pain. Pain Med. 15, 1359–1364 (2014).
41. Olesen, S. S., Poulsen, J. L., Broberg, M. C., Madzak, A. & Drewes, A. M. Opioid treatment and hypoalbuminemia are associated with increased hospitalisation rates in chronic pancreatitis outpatients. Pancreatology 16, 807–813 (2016).
42. Morley, K. I., Ferris, J. A., Winstock, A. R. & Lynskey, M. T. Polysubstance use and misuse or abuse of prescription opioid analgesics: a multi-level analysis of international data. Pain 158, 1138–1144 (2017).
43. Sharma, A. & Jamal, M. M. Opioid induced bowel disease: a twenty-first century physicians' dilemma. Considering pathophysiology and treatment strategies. Curr. Gastroenterol. Rep. 15, 334 (2013).
44. American Pain Society & American Academy of Pain Medicine. Guideline for the use of chronic opioid therapy in chronic noncancer pain: evidence review (American Pain Society, 2009).
45. Wilder-Smith, C. H., Hill, L., Osler, W. & O'Keefe, S. Effect of tramadol and morphine on pain and gastrointestinal motor function in patients with chronic pancreatitis. Dig. Dis. Sci. 44, 1107–1116 (1999).

46. Tennant, F. Why oral opioids may not be effective in a subset of chronic pain patients. *Postgrad. Med.* **128**, 18–22 (2016).

47. Crocker, J. A., Yu, H., Conaway, M., Tuskey, A. G. & Behm, B. W. Narcotic use and misuse in Crohn's disease. *Inflamm. Bowel Dis.* **20**, 2234–2238 (2014).

48. Surdea-Blaga, T., Baban, A. & Dumitrascu, D. Psychosocial determinants of irritable bowel syndrome. *World J. Gastroenterol.* **18**, 616–626 (2012).

49. Targownik, L. E., Nugent, Z., Singh, H., Bugden, S. & Bernstein, C. N. The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis. *Am. J. Gastroenterol.* **109**, 1613–1620 (2014).

50. Edlund, M. J. *et al.* The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. *Clin. J. Pain* **30**, 557–564 (2014).

51. Cook, S. F. *et al.* Gastrointestinal side effects in chronic opioid users: results from a population-based survey. *Aliment. Pharmacol. Ther.* **27**, 1224–1232 (2008).

52. Kraichely, R. E., Arora, A. S. & Murray, J. A. Opiate-induced oesophageal dysmotility. *Aliment. Pharmacol. Ther.* **31**, 601–606 (2010).

53. Gaertner, J. *et al.* Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. *J. Clin. Gastroenterol.* **49**, 9–16 (2015).

54. Mearin, F. *et al.* Bowel disorders. *Gastroenterology* **150**, 1393–1407.e5 (2016).

55. Khemani, D. *et al.* Opioid analgesic use among patients presenting with acute abdominal pain and factors associated with surgical diagnoses. *Neurogastroenterol. Motil.* **29**, e13000 (2016).

56. Rauck, R. L., Hong, K. J. & North, J. Opioid-induced constipation survey in patients with chronic noncancer pain. *Pain Pract.* **17**, 329–335 (2017).

57. Ratuapli, S. K. *et al.* Opioid-induced esophageal dysfunction (OIED) in patients on chronic opioids. *Am. J. Gastroenterol.* **110**, 979–984 (2015).

58. Fujioka, K. *et al.* Patients with short bowel on narcotics during 2 randomized trials have abdominal complaints independent of teduglutide. *JPEN J. Parenter. Enteral. Nutr.* http://dx.doi.org/10.1177/0148607116663481 (2016).

59. Leppert, W. The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities. *Contemp. Oncol.* **16**, 125–131 (2012).

60. Sobczak, M., Sałaga, M., Storr, M. A. & Fichna, J. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. *J. Gastroenterol.* **49**, 24–45 (2014).

61. Galligan, J. J. & Akbarali, H. I. Molecular physiology of enteric opioid receptors. *Am. J. Gastroenterol. Suppl.* **2**, 17–21 (2014).

62. Holzer, P. New approaches to the treatment of opioid-induced constipation. *Eur. Rev. Med. Pharmacol. Sci.* **12** (Suppl. 1), 119–127 (2008).

63. Browning, K. N. & Travagli, R. A. Central nervous system control of gastrointestinal motility and secretion and modulation of gastrointestinal functions. *Compr. Physiol.* **4**, 1339–1368 (2014).

64. Barrett, K. E. New insights into the pathogenesis of intestinal dysfunction: secretory diarrhea and cystic fibrosis. *World J. Gastroenterol.* **6**, 470–474 (2000).

65. Zhou, P., Li, T., Su, R. & Gong, Z. Effects of thienorphine on contraction of the guinea pig sphincter of Oddi, choledochus and gall bladder. *Eur. J. Pharmacol.* **737**, 22–28 (2014).

66. Joehl, R. J., Koch, K. L. & Nahrwold, D. L. Opioid drugs cause bile duct obstruction during hepatobiliary scans. *Am. J. Surg.* **147**, 134–138 (1984).

67. Mittal, R. K., Frank, E. B., Lange, R. C. & McCallum, R. W. Effects of morphine and naloxone on esophageal motility and gastric emptying in man. *Dig. Dis. Sci.* **31**, 936–942 (1986).

68. Penagini, R., Bartesaghi, B., Zannini, P., Negri, G. & Bianchi, P. A. Lower oesophageal sphincter hypersensitivity to opioid receptor stimulation in patients with idiopathic achalasia. *Gut* **34**, 16–20 (1993).

69. Schoenfeld, P. S. Advances in IBS 2016: a review of current and emerging data. *Gastroenterol. Hepatol.* **12** (Suppl. 3), 1–11 (2016).

70. Cash, B. D., Lacy, B. E., Schoenfeld, P. S., Dove, L. S. & Covington, P. S. Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea. *Am. J. Gastroenterol.* **112**, 365–374 (2017).

71. Chandok, N. & Watt, K. D. Pain management in the cirrhotic patient: the clinical challenge. *Mayo Clin. Proc.* **85**, 451–458 (2010).

72. Bosilkovska, M., Walder, B., Besson, M., Daali, Y. & Desmeules, J. Analgesics in patients with hepatic impairment: pharmacology and clinical implications. *Drugs* **72**, 1645–1669 (2012).

73. Verbeeck, R. K. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. *Eur. J. Clin. Pharmacol.* **64**, 1147–1161 (2008).

74. Hasselstrom, J. *et al.* The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. *Br. J. Clin. Pharmacol.* **29**, 289–297 (1990).

75. Soleimanpour, H., Safari, S., Shahsavari Nia, K., Sanaie, S. & Alavian, S. M. Opioid drugs in patients with liver disease: a systematic review. *Hepat. Mon.* **16**, e32636 (2016).

76. Noble, M. *et al.* Long-term opioid management for chronic noncancer pain. *Cochrane Database Syst. Rev.* **1**, CD006605 (2010).

77. Ling, G. S., Paul, D., Simantov, R. & Pasternak, G. W. Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. *Life Sci.* **45**, 1627–1636 (1989).

78. Schneider, J. P. & Kirsh, K. L. Defining clinical issues around tolerance, hyperalgesia, and addiction: a quantitative and qualitative outcome study of long-term opioid dosing in a chronic pain practice. *J. Opioid Manag.* **6**, 385–395 (2010).

79. Camilleri, M. *et al.* Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. *Neurogastroenterol. Motil.* **26**, 1386–1395 (2014).

80. Harada, Y. *et al.* Mashiningan improves opioid-induced constipation in rats by activating cystic fibrosis transmembrane conductance regulator chloride channel. *J. Pharmacol. Exp. Ther.* **362**, 78–84 (2017).

81. Grunkemeier, D. M., Cassara, J. E., Dalton, C. B. & Drossman, D. A. The narcotic bowel syndrome: clinical features, pathophysiology, and management. *Clin. Gastroenterol. Hepatol.* **5**, 1126–1139 (2007).

82. Keefer, L. *et al.* Centrally mediated disorders of gastrointestinal pain. *Gastroenterology* **150**, 1408–1419 (2016).

83. Szigethy, E., Schwartz, M. & Drossman, D. Narcotic bowel syndrome and opioid-induced constipation. *Curr. Gastroenterol. Rep.* **16**, 410 (2014).

84. Drossman, D. & Szigethy, E. The narcotic bowel syndrome: a recent update. *Am. J. Gastroenterol. Suppl.* **2**, 22–30 (2014).

85. Drossman, D. A. Functional gastrointestinal disorders: history, pathophysiology, clinical features & Rome IV. *Gastroenterology* **150**, 1262–1279.e2 (2016).

86. Low, Y., Clarke, C. F. & Huh, B. K. Opioid-induced hyperalgesia: a review of epidemiology, mechanisms and management. *Singapore Med. J.* **53**, 357–360 (2012).

87. Watkins, L. R. & Maier, S. F. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. *Physiol. Rev.* **82**, 981–1011 (2002).

88. Crain, S. M. & Shen, K. F. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. *Pain* **84**, 121–131 (2000).

89. Ossipov, M. H., Lai, J., King, T., Vanderah, T. W. & Porreca, F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. *Biopolymers* **80**, 319–324 (2005).

90. Kurlander, J. E. & Drossman, D. A. Diagnosis and treatment of narcotic bowel syndrome. *Nat. Rev. Gastroenterol. Hepatol.* **11**, 410–418 (2014).

91. Watkins, L. R., Milligan, E. D. & Maier, S. F. Glial activation: a driving force for pathological pain. *Trends Neurosci.* **24**, 450–455 (2001).

92. Rattan, A. K. & Tejwani, G. A. Effect of chronic treatment with morphine, midazolam and both together on dynorphin(1–13) levels in the rat. *Brain Res.* **754**, 239–244 (1997).

93. Agostini, S. *et al.* Evidence of central and peripheral sensitization in a rat model of narcotic bowel-like syndrome. *Gastroenterology* **139**, 553–563.e5 (2010).

94. Hutchinson, M. R. *et al.* Evidence that opioids may have toll-like receptor 4 and MD-2 effects. *Brain Behav. Immun.* **24**, 83–95 (2010).

95. Hutchinson, M. R. *et al.* Opioid activation of toll-like receptor 4 contributes to drug reinforcement. *J. Neurosci.* **32**, 11187–11200 (2012).

96. Mattioli, T. A. *et al.* Toll-like receptor 4 mutant and null mice retain morphine-induced tolerance, hyperalgesia, and physical dependence. *PLoS ONE* **9**, e97361 (2014).

97. Farmer, A. D., Ferdinand, E. & Aziz, Q. Opioids and the gastrointestinal tract — a case of narcotic bowel syndrome and literature review. *J. Neurogastroenterol. Motil.* **19**, 94–98 (2013).

98. Kotalik, J. Controlling pain and reducing misuse of opioids: ethical considerations. *Can. Fam. Physician* **58**, 381–385 (2012).

99. Dowell, D., Haegerich, T. M. & Chou, R. CDC guideline for prescribing opioids for chronic pain — United States, 2016. *JAMA* **315**, 1624–1645 (2016).

100. Murthy, V. H. Ending the opioid epidemic — a call to action. *N. Engl. J. Med.* **375**, 2413–2415 (2016).

101. Ballantyne, J. C. & Fleisher, L. A. Ethical issues in opioid prescribing for chronic pain. *Pain* **148**, 365–367 (2010).

102. Zgierska, A., Miller, M. & Rabago, D. Patient satisfaction, prescription drug abuse, and potential unintended consequences. *JAMA* **307**, 1377–1378 (2012).

103. Kelly, S., Johnson, G. T. & Harbison, R. D. "Pressured to prescribe": the impact of economic and regulatory factors on South-Eastern ED physicians when managing the drug seeking patient. *J. Emerg. Trauma Shock* **9**, 58–63 (2016).

104. Kolodny, A. *et al.* The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. *Annu. Rev. Publ. Health* **36**, 559–574 (2015).

105. Drossman, D. A. *et al.* Diagnosis, characterization, and 3-month outcome after detoxification of 39 patients with narcotic bowel syndrome. *Am. J. Gastroenterol.* **107**, 1426–1440 (2012).

106. U.S. Food and Drug Administration. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use. *U.S. Food and Drug Administration* https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm518697.htm (2016).

107. Tornblom, H. & Drossman, D. A. Centrally targeted pharmacotherapy for chronic abdominal pain. *Neurogastroenterol. Motil.* **27**, 455–467 (2015).

108. Dekel, R., Drossman, D. A. & Sperber, A. D. The use of psychotropic drugs in irritable bowel syndrome. *Expert Opin. Investigat. Drugs* **22**, 329–339 (2013).

109. Stoicea, N. *et al.* Opioid-induced hyperalgesia in chronic pain patients and the mitigating effects of gabapentin. *Front. Pharmacol.* **6**, 104 (2015).

110. Arumugam, S., Lau, C. S. & Chamberlain, R. S. Use of preoperative gabapentin significantly reduces postoperative opioid consumption: a meta-analysis. *J. Pain Res.* **9**, 631–640 (2016).

111. Erlendson, M. J. *et al.* Palonosetron and hydroxyzine pre-treatment reduces the objective signs of experimentally-induced acute opioid withdrawal in humans: a double-blinded, randomized, placebo-controlled crossover study. *Am. J. Drug Alcohol Abuse* **43**, 78–86 (2017).

112. Gowing, L., Ali, R., White, J. M. & Mbewe, D. Buprenorphine for managing opioid withdrawal. *Cochrane Database Syst. Rev.* **2**, CD002025 (2017).

113. Xie, C. *et al.* Efficacy and safety of antidepressants for the treatment of Irritable Bowel Syndrome: a meta-analysis. *PLoS ONE* **10**, e0127815 (2015).

114. Thorkelson, G., Bielefeldt, K. & Szigethy, E. Empirically supported use of psychiatric medications in adolescents and adults with IBD. *Inflamm. Bowel Dis.* **22**, 1509–1522 (2016).

115. Cheng, Y. *et al.* Association between TLR2 and TLR4 gene polymorphisms and the susceptibility to Inflammatory Bowel Disease: a meta-analysis. *PLoS ONE* **10**, e0126803 (2015).

116. Daghaghzadeh, H. *et al.* Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: a double-blind controlled study. *J. Res. Med. Sci.* **20**, 595–601 (2015).

117. Talley, N. J. *et al.* Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. *Gastroenterology* **149**, 340–349.e342 (2015).

118. Talley, N. J. *et al.* Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. *Dig. Dis. Sci.* **53**, 108–115 (2008).

119. Masand, P. S. *et al.* A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. *Psychosomatics* **50**, 78–86 (2009).

120. Grover, M. & Camilleri, M. Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases. *J. Gastroenterol.* **48**, 177–181 (2013).

121. Grover, M. *et al.* Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. *Dig. Dis. Sci.* **54**, 1284–1291 (2009).

122. Gurusamy, K. S., Lusuku, C. & Davidson, B. R. Pregabalin for decreasing pancreatic pain in chronic pancreatitis. *Cochrane Database Syst. Rev.* **2**, CD011522 (2016).

123. Olesen, S. S. *et al.* Randomised clinical trial: pregabalin attenuates experimental visceral pain through sub-cortical mechanisms in patients with painful chronic pancreatitis. *Aliment. Pharmacol. Ther.* **34**, 878–887 (2011).

124. Gale, J. D. & Houghton, L. A. Alpha 2 delta ($\alpha_2\delta$) Ligands, gabapentin and pregabalin: what is the evidence for potential use of these ligands in irritable bowel syndrome. *Front. Pharmacol.* **2**, 28 (2011).

125. Takemura, Y. *et al.* Effects of gabapentin on brain hyperactivity related to pain and sleep disturbance under a neuropathic pain-like state using fMRI and brain wave analysis. *Synapse* **65**, 668–676 (2011).

126. Saito, Y. A. *et al.* A placebo-controlled trial of pregabalin for irritable bowel syndrome. *Am. J. Gastroenterol. Suppl.* **111**, S236 (2016).

127. Paul, S. P. & Basude, D. Non-pharmacological management of abdominal painrelated functional gastrointestinal disorders in children. *World J. Pediatr.* **12**, 389–398 (2016).

128. Srinath, A. I., Walter, C., Newara, M. C. & Szigethy, E. M. Pain management in patients with inflammatory bowel disease: insights for the clinician. *Therap. Adv. Gastroenterol.* **5**, 339–357 (2012).

129. Ford, A. C. *et al.* Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. *Am. J. Gastroenterol.* **109**, 1350–1365 (2014).

130. Ruepert, L. *et al.* Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. *Cochrane Database Syst. Rev.* **8**, CD003460 (2011).

131. Brennan, B. P. *et al.* Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. *Hum. Psychopharmacol.* **24**, 423–428 (2009).

132. Kaplan, A., Franzen, M. D., Nickell, P. V., Ransom, D. & Lebovitz, P. J. An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder. *Int. J. Psychiatry Clin. Pract.* **18**, 11–15 (2014).

133. Lewis-Fernandez, R. *et al.* An open-label pilot study of duloxetine in patients with irritable bowel syndrome and comorbid major depressive disorder. *J. Clin. Psychopharmacol.* **36**, 710–715 (2016).

134. Lacy, B. E., Chey, W. D. & Lembo, A. J. New and emerging treatment options for Irritable Bowel Syndrome. *Gastroenterol. Hepatol.* **11** (Suppl. 2), 1–19 (2015).

135. Noyman-Veksler, G. *et al.* Role of pain-based catastrophizing in pain, disability, distress, and suicidal ideation. *Psychiatry* **80**, 155–170 (2017).

136. Cheng, C., Hui, W. & Lam, S. Perceptual style and behavioral pattern of individuals with functional gastrointestinal disorders. *Health Psych.* **19**, 146–154 (2000).

137. Sandner-Kiesling, A. *et al.* Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. *Int. J. Clin. Pract.* **64**, 763–774 (2010).

138. Ford, A. C., Brenner, D. M. & Schoenfeld, P. S. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. *Am. J. Gastroenterol.* **108**, 1566–1574 (2013).

139. Mehta, N., O'Connell, K., Giambrone, G. P., Baqai, A. & Diwan, S. Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review. *Postgrad. Med.* **128**, 282–289 (2016).

140. Kraft, M. D. Methylnaltrexone, a new peripherally acting mu-opioid receptor antagonist being evaluated for the treatment of postoperative ileus. *Expert Opin. Invest. Drugs* **17**, 1365–1377 (2008).

141. Poulsen, J., Brock, C., Olesen, A. E., Nilsson, M. & Drewes, A. M. Evolving paradigms in the treatment of opioid-induced bowel dysfunction. *Therap. Adv. Gastroenterol.* **8**, 360–372 (2015).

142. Sloots, C. E., Rykx, A., Cools, M., Kerstens, R. & De Pauw, M. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. *Dig. Dis. Sci.* **55**, 2912–2921 (2010).

143. Sajid, M. S., Hebbar, M., Baig, M. K., Li, A. & Philipose, Z. Use of prucalopride for chronic constipation: a systematic review and meta-analysis of published randomized, controlled trials. *J. Neurogastroenterol. Motil.* **22**, 412–422 (2016).

144. Nelson, A. D. & Camilleri, M. Opioid-induced constipation: advances and clinical guidance. *Ther. Adv. Chron. Dis.* **7**, 121–134 (2016).

145. Argoff, C. E. *et al.* Consensus recommendations on initiating prescription therapies for opioid-induced constipation. *Pain Med.* **16**, 2324–2337 (2015).

146. Ducrotte, P. & Causse, C. The Bowel Function Index: a new validated scale for assessing opioid-induced constipation. *Curr. Med. Res. Opin.* **28**, 457–466 (2012).

147. Slappendel, R., Simpson, K., Dubois, D. & Keininger, D. L. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. *Eur. J. Pain* **10**, 209–217 (2006).

148. Keefer, L. & Mandal, S. The potential role of behavioural therapies in the management of centrally mediated abdominal pain. *Neurogastroenterol. Motil.* **27**, 313–323 (2015).

149. Eccleston, C., Morley, S. J. & Williams, A. C. Psychological approaches to chronic pain management: evidence and challenges. *Br. J. Anaesth.* **111**, 59–63 (2013).

150. Ehde, D. M., Dillworth, T. M. & Turner, J. A. Cognitive-behavioral therapy for individuals with chronic pain: efficacy, innovations, and directions for research. *Am. Psychol.* **59**, 153–166 (2014).

151. Kerns, R. D., Sellinger, J. & Goodin, B. R. Psychological treatment of chronic pain. *Annu. Rev. Clin. Psychol.* **7**, 411–434 (2011).

152. Tang, Q. L., Lin, G. Y. & Zhang, M. Q. Cognitive-behavioral therapy for the management of irritable bowel syndrome. *World J. Gastroenterol.* **19**, 8605–8610 (2013).

153. Laird, K. T., Tanner-Smith, E. E., Russell, A. C., Hollon, S. D. & Walker, L. S. Short-term and long-term efficacy of psychological therapies for Irritable Bowel Syndrome: a systematic review and meta-analysis. *Clin. Gastroenterol. Hepatol.* **14**, 937–947.e4 (2016).

154. Altayar, O., Sharma, V., Prokop, L. J., Sood, A. & Murad, M. H. Psychological therapies in patients with irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. *Gastroenterol. Res. Pract.* **2015**, 549308 (2015).

155. Palsson, O. S. & Whitehead, W. E. Psychological treatments in functional gastrointestinal disorders: a primer for the gastroenterologist. *Clin. Gastroenterol. Hepatol.* **11**, 208–216 (2013).

156. Regueiro, M., Greer, J. B. & Szigethy, E. Etiology and treatment of pain and psychosocial issues in patients with inflammatory bowel diseases. *Gastroenterology* **152**, 430–439.e4 (2017).

157. Knowles, S. R., Monshat, K. & Castle, D. J. The efficacy and methodological challenges of psychotherapy for adults with inflammatory bowel disease: a review. *Inflamm. Bowel Dis.* **19**, 2704–2715 (2013).

158. Mikocka-Walus, A., Andrews, J. M. & Bampton, P. Cognitive behavioral therapy for IBD. *Inflamm. Bowel Dis.* **22**, E5–E6 (2016).

159. Lee, H. H., Choi, Y. Y. & Choi, M. G. The efficacy of hypnotherapy in the treatment of Irritable Bowel Syndrome: a systematic review and meta-analysis. *J. Neurogastroenterol. Motil.* **20**, 152–162 (2014).

160. Webb, A. N., Kukuruzovic, R. H., Catto-Smith, A. G. & Sawyer, S. M. Hypnotherapy for treatment of irritable bowel syndrome. *Cochrane Database Syst. Rev.* **4**, CD005110 (2007).

161. Aucoin, M., Lalonde-Parsi, M. J. & Cooley, K. Mindfulness-based therapies in the treatment of functional gastrointestinal disorders: a meta-analysis. *Evid. Based Complement. Alternat. Med.* **2014**, 140724 (2014).

162. Goyal, M. *et al.* Meditation programs for psychological stress and well-being: a systematic review and meta-analysis. *JAMA Intern. Med.* **174**, 357–368 (2014).

163. Bawa, F. L. *et al.* Does mindfulness improve outcomes in patients with chronic pain? Systematic review and meta-analysis. *Br. J. Gen. Pract.* **65**, e387–e400 (2015).

164. Palsson, O. S. Hypnosis treatment of gastrointestinal disorders: a comprehensive review of the empirical evidence. *Am. J. Clin. Hypn.* **58**, 134–158 (2015).

165. Keefer, L. *et al.* Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis. *Aliment. Pharmacol. Ther.* **38**, 761–771 (2013).

166. Jedel, S. *et al.* A randomized controlled trial of mindfulness-based stress reduction to prevent flare-up in patients with inactive ulcerative colitis. *Digestion* **89**, 142–155 (2014).

167. Berrill, J. W., Sadlier, M., Hood, K. & Green, J. T. Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. *J. Crohns Colitis* **8**, 945–955 (2014).

168. Gerbarg, P. L. *et al.* The effect of breathing, movement, and meditation on psychological and physical symptoms and inflammatory biomarkers in Inflammatory Bowel Disease: a randomized controlled trial. *Inflamm. Bowel Dis.* **21**, 2886–2896 (2015).

169. Jones, M., Koloski, N., Boyce, P. & Talley, N. J. Pathways connecting cognitive behavioral therapy and change in bowel symptoms of IBS. *J. Psychosom. Res.* **70**, 278–285 (2011).

170. Chang, L. The role of stress on physiological responses and clinical symptoms in irritable bowel syndrome. *Gastroenterology* **140**, 761–765 (2011).

171. Bonaz, B. L. & Bernstein, C. N. Brain-gut interactions in inflammatory bowel disease. *Gastroenterology* **144**, 36–49 (2013).

172. Carabotti, M., Scirocco, A., Maselli, M. & Severi, C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. *Ann. Gastroenterol.* **28**, 203–209 (2015).

173. Uc, A. *et al.* Chronic pancreatitis in the 21st century — research challenges and opportunities: summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. *Pancreas* **45**, 1365–1375 (2016).

174. Palsson, O. S. & van Tilburg, M. Hypnosis and guided imagery treatment for gastrointestinal disorders: experience with scripted protocols developed at the University of North Carolina. *Am. J. Clin. Hypn.* **58**, 5–21 (2015).

175. Ljotsson, B. *et al.* Internet-delivered exposure-based treatment versus stress management for irritable bowel syndrome: a randomized trial. *Am. J. Gastroenterol.* **106**, 1481–1491 (2011).

176. Ljotsson, B. *et al.* Long-term follow-up of internet-delivered exposure and mindfulness based treatment for irritable bowel syndrome. *Behav. Res. Ther.* **49**, 58–61 (2011).

177. Eccleston, C. *et al.* Psychological therapies (Internet-delivered) for the management of chronic pain in adults. *Cochrane Database Syst. Rev.* **2**, CD010152 (2014).

178. Krupnick, J. L. *et al.* The role of the therapeutic alliance in psychotherapy and pharmacotherapy outcome: findings in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. *J. Consult. Clin. Psychol.* **64**, 532–539 (1996).

179. Esquibel, A. Y. & Borkan, J. Doctors and patients in pain: conflict and collaboration in opioid prescription in primary care. *Pain* **155**, 2575–2582 (2014).

180. Bäckryd, E. "Professional Helper" or "Helping Professional?" The patient-physician relationship in the chronic pain setting, with special reference to the current opioid debate. *J. Contin. Educ. Health Prof.* **36**, 133–137 (2016).

181. Drossman, D. A. 2012 David Sun lecture: helping your patient by helping yourself — how to improve the patient-physician relationship by optimizing communication skills. *Am. J. Gastroenterol.* **108**, 521–528 (2013).

182. Frantsve, L. M. & Kerns, R. D. Patient-provider interactions in the management of chronic pain: current findings within the context of shared medical decision making. *Pain Med.* **8**, 25–35 (2007).

183. Reed-Knight, B., Claar, R. L., Schurman, J. V. & van Tilburg, M. A. Implementing psychological therapies for functional GI disorders in children and adults. *Expert Rev. Gastroenterol. Hepatol.* **10**, 981–984 (2016).

184. Martins, S. S. *et al.* Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the National Epidemiologic Study on Alcohol and Related Conditions. *Psychol. Med.* **42**, 1261–1272 (2012).

185. Wasan, A. D. *et al.* Psychiatric comorbidity is associated prospectively with diminished opioid analgesia and increased opioid misuse in patients with chronic low back pain. *Anesthesiology* **123**, 861–872 (2015).

186. Mason, M. J. *et al.* Depression moderates the relationship between pain and the nonmedical use of opioid medication among adult outpatients. *J. Addict. Med.* **10**, 408–413 (2016).

187. Arteta, J., Cobos, B., Hu, Y., Jordan, K. & Howard, K. Evaluation of how depression and anxiety mediate the relationship between pain catastrophizing and prescription opioid misuse in a chronic pain population. *Pain Med.* **17**, 295–303 (2016).

188. Rosenblum, A., Marsch, L. A., Joseph, H. & Portenoy, R. K. Opioids and the treatment of chronic pain: controversies, current status, and future directions. *Exp. Clin. Psychopharmacol.* **16**, 405–416 (2008).

189. Cowan, D. T., Allan, L. G., Libretto, S. E. & Griffiths, P. Opioid drugs: a comparative survey of therapeutic and "street" use. *Pain Med.* **2**, 193–203 (2001).

190. Lee, E. B., An, W., Levin, M. E. & Twohig, M. P. An initial meta-analysis of Acceptance and Commitment Therapy for treating substance use disorders. *Drug Alcohol Depend.* **155**, 1–7 (2015).

191. Jones, C. M. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers — United States, 2002–2004 and 2008–2010. *Drug Alcohol Depend.* **132**, 95–100 (2013).

192. Des Jarlais, D. C. *et al.* HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. *Am. J. Publ. Health* **95**, 1439–1444 (2005).

193. Hagan, H. *et al.* Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. *J. Infect. Dis.* **201**, 378–385 (2010).

194. Paicius, R. M., Bernstein, C. A. & Lempert-Cohen, C. Peripheral nerve field stimulation in chronic abdominal pain. *Pain Physician* **9**, 261–266 (2006).

195. Kapural, L. & Jolly, S. Interventional pain management approaches for control of chronic pancreatic pain. *Curr. Treat. Opt. Gastroenterol.* **14**, 360–370 (2016).

196. Simis, M. *et al.* Investigation of central nervous system dysfunction in chronic pelvic pain using magnetic resonance spectroscopy and noninvasive brain stimulation. *Pain Pract.* **15**, 423–432 (2015).

197. Moreno-Duarte, I. *et al.* Targeted therapies using electrical and magnetic neural stimulation for the treatment of chronic pain in spinal cord injury. *Neuroimage* **85**, 1003–1013 (2014).

198. Gray, A. M. *et al.* Deep brain stimulation as a treatment for neuropathic pain: a longitudinal study addressing neuropsychological outcomes. *J. Pain* **15**, 283–292 (2014).

199. Butler, S. F., Budman, S. H., Fanciullo, G. J. & Jamison, R. N. Cross validation of the Current Opioid Misuse Measure (COMM) to monitor chronic pain patients on opioid therapy. *Clin. J. Pain* **26**, 770–776 (2010).

200. Butler, S. F., Fernandez, K., Benoit, C., Budman, S. H. & Jamison, R. N. Validation of the Revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). *J. Pain* **9**, 360–372 (2008).

201. Bao, Y. *et al.* Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. *Health Aff.* **35**, 1045–1051 (2016).

202. Kovitwanichkanont, T. & Day, C. A. Prescription opioid misuse and public health approach in Australia. *Subst. Use Misuse* http://dx.doi.org/10.1080/10826084.2017.1305415 (2017).

203. European Monitoring Centre for Drugs and Drug Addiction. Our activities — ongoing projects and programmes. *European Monitoring Centre for Drugs and Drug Addiction* http://www.emcdda.europa.eu/activities (2017).

204. Novak, S. P. *et al.* Nonmedical use of prescription drugs in the European Union. *BMC Psychiatry* **16**, 274 (2016).

205. University of Wisconsin–Madison Pain & Policy Studies Group. Custom consumption graphs for opioid medicines. *Pain & Policy Studies Group* https://ppsg-chart.medicine.wisc.edu/ (2017).

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

www.manaraa.com